Christopher Kemp

Scientific Advisor & Co-Founder at SEngine Precision Medicine

Dr. Kemp has studied the genetic and molecular basis of cancer for more than 25 years and has been internationally recognized for his pioneering research on tumor suppressor genes. Dr. Kemp leads a program in functional genomics to identify new therapeutic targets for human cancer, supported largely by a U01 grant in the Cancer Target Discovery and Development Network. Dr. Kemp is a Full Member in the Divisions of Human Biology and Public Health Science at the Fred Hutchinson Cancer Research Center and is an Adjunct Professor in the Department of Pathology at the University of Washington.


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


SEngine Precision Medicine

SEngine Precision Medicine has engineered an innovative approach to identify and develop the next generation of cancer targeted drugs.


Employees

11-50

Links